Compare TLSA & PETS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLSA | PETS |
|---|---|---|
| Founded | 2013 | 1996 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail-Drug Stores and Proprietary Stores |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.1M | 61.6M |
| IPO Year | 2017 | 2003 |
| Metric | TLSA | PETS |
|---|---|---|
| Price | $1.28 | $2.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 166.2K | 72.2K |
| Earning Date | 05-04-2026 | 06-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.92 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $273,800,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.14 | $1.57 |
| 52 Week High | $2.60 | $4.32 |
| Indicator | TLSA | PETS |
|---|---|---|
| Relative Strength Index (RSI) | 49.00 | 42.48 |
| Support Level | $1.19 | $2.19 |
| Resistance Level | $1.44 | $2.45 |
| Average True Range (ATR) | 0.10 | 0.10 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 42.58 | 33.57 |
Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.